1. Stem-cell Biology in Normal and Malignant Hematopoiesis

  1. Stefan Faderl MD Associate Professor and
  2. Hagop Kantarjian MD Chairman Professor
  1. Amer Zeidan MD1,2 and
  2. Meir Wetzler MD, FACP Professor Chief3

Published Online: 4 JAN 2011

DOI: 10.1002/9781444327359.ch1

Leukemias: Principles and Practice of Therapy

Leukemias: Principles and Practice of Therapy

How to Cite

Zeidan, A. and Wetzler, M. (2010) Stem-cell Biology in Normal and Malignant Hematopoiesis, in Leukemias: Principles and Practice of Therapy (eds S. Faderl and H. Kantarjian), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444327359.ch1

Editor Information

  1. Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Author Information

  1. 1

    Academic Hospitalist, Division of Hospital Medicine, General Medicine Unit, Rochester General Hospital, Rochester, New York, USA

  2. 2

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA

  3. 3

    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA

Publication History

  1. Published Online: 4 JAN 2011
  2. Published Print: 26 NOV 2010

ISBN Information

Print ISBN: 9781405182355

Online ISBN: 9781444327359



  • hematopoiesis;
  • hematopoietic stem cell (HSC);
  • leukemic stem cell (LSC);
  • targeted therapy;
  • bone marrow niche;
  • self-renewal;
  • BMS-214662;
  • Parthenolide;
  • TDZD-8;
  • anti-CD44


Hematopoiesis is the process by which all the cellular blood elements are produced from the hematopoietic stem cells (HSCs). Similarly, in several forms of leukemia, the cellular components are derived from leukemia stem cells (LSCs). Normal HSCs and LSCs share many qualities, including quiescence, self-renewal, extensive proliferative capacity, the ability to give rise to differentiated progeny in a hierarchical pattern, and resistance to most of the traditional chemotherapeutic agents used in the management of leukemias; the latter is the most important contributor for treatment failure and relapse in leukemias. Curing most forms of leukemia requires the development of effective therapeutic modalities that specifically target the LSCs. The efforts to develop such agents are hindered by the potential toxicity to the normal HSCs because of the close similarities between normal HSCs and LSCs. Nevertheless, several promising novel agents that are specifically active against LSCs have been described in recent years.